Brainstorm Cell Therapeutics Inc. (BCLI)

3.92
0.01 0.25
NASDAQ : Health Technology
Prev Close 3.93
Open 3.97
Day Low/High 3.93 / 3.97
52 Wk Low/High 2.92 / 4.50
Volume 2.40K
Avg Volume 51.20K
Exchange NASDAQ
Shares Outstanding 22.61M
Market Cap 85.45M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BrainStorm Announces Financial Results For The Third Quarter Of 2019 And Provides A Corporate Update

BrainStorm Announces Financial Results For The Third Quarter Of 2019 And Provides A Corporate Update

Conference Call and Webcast Today at 8:00 a.m.

BrainStorm Announces Grant Of A New Japanese Patent For NurOwn®

BrainStorm Announces Grant Of A New Japanese Patent For NurOwn®

NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc To Present At The 7th International Stem Cell Meeting

BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc To Present At The 7th International Stem Cell Meeting

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc .

BrainStorm Cell Therapeutics To Announce Third Quarter Financial Results And Provide A Comprehensive Corporate Update

BrainStorm Cell Therapeutics To Announce Third Quarter Financial Results And Provide A Comprehensive Corporate Update

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc .

NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue

NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue

NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics To Present At The Dawson James Securities 5th Annual Small Cap Growth Conference

BrainStorm Cell Therapeutics To Present At The Dawson James Securities 5th Annual Small Cap Growth Conference

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics' President And CEO To Be Featured As Keynote Speaker At Cell Series UK 2019

BrainStorm Cell Therapeutics' President And CEO To Be Featured As Keynote Speaker At Cell Series UK 2019

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Presentations At Neuromuscular Drug Development Summit

BrainStorm Cell Therapeutics Presentations At Neuromuscular Drug Development Summit

NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.

BrainStorm's NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled

BrainStorm's NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled

NEW YORK, Oct. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc .

BrainStorm Announces Notice Of US Patent Allowance For NurOwn® Cellular Therapeutic Technology Platform

BrainStorm Announces Notice Of US Patent Allowance For NurOwn® Cellular Therapeutic Technology Platform

NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics To Present NurOwn® Phase 2 Biomarker Data At North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting

BrainStorm Cell Therapeutics To Present NurOwn® Phase 2 Biomarker Data At North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting

NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Support For FDA Guidelines On ALS Drug Development

BrainStorm Cell Therapeutics Announces Support For FDA Guidelines On ALS Drug Development

BrainStorm Holds a Roundtable Discussion with ALS Advocacy Group Leaders

BrainStorm Strengthens Senior Executive Management Team With The Appointment Of Preetam Shah, Ph.D., M.B.A., As Chief Financial Officer

BrainStorm Strengthens Senior Executive Management Team With The Appointment Of Preetam Shah, Ph.D., M.B.A., As Chief Financial Officer

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics To Present Late Breaking News EPoster At The 35th ECTRIMS Congress

BrainStorm Cell Therapeutics To Present Late Breaking News EPoster At The 35th ECTRIMS Congress

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Financial Results For The Second Quarter Of 2019 And Provides A Corporate Update

BrainStorm Announces Financial Results For The Second Quarter Of 2019 And Provides A Corporate Update

Conference Call and Webcast Today at 8:00 a.m.

Third Clinical Site Initiated For BrainStorm Cell Therapeutic's Phase 2 Progressive MS Study

Third Clinical Site Initiated For BrainStorm Cell Therapeutic's Phase 2 Progressive MS Study

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company has...

Brainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial

Brainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial

Brainstorm's NurOwn is a personalized stem cell treatment designed to slow the progression of ALS, a fatal neurodegenerative disease.

Brainstorm Cell Therapeutics (BCLI) Stock Plummets Ahead of ALS Trial Results

Brainstorm Cell Therapeutics (BCLI) Stock Plummets Ahead of ALS Trial Results

Brainstorm Cell Therapeutics (BCLI) is scheduled to announce results from its phase II ALS trial on Monday.

Brainstorm Recycles ALS Stem Cell Data to Boost Sagging Stock

Brainstorm Recycles ALS Stem Cell Data to Boost Sagging Stock

A much-hyped press conference reveals nothing new about Brainstorm's stem-cell therapy for ALS.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are poisted to trade higher from current levels.

Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results

Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results

Brainstorm Cell Therapeutics (BCLI) shares are gaining as the company prepares to release a report on its phase 2a ALS treatment study.

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

3 Stocks Under $10 Triggering Big Breakout Trades

3 Stocks Under $10 Triggering Big Breakout Trades

Keep these under-$10 stocks on your breakout trading radar.

Neuralstem Stock Plunges After Latest Study on ALS Drug

Neuralstem Stock Plunges After Latest Study on ALS Drug

Neuralstem is providing an overly optimistic picture about its surgical stem-cell therapy for amyotrophic lateral sclerosis (ALS), the degenerative and fatal nerve disease.

3 Biotech Stocks Under $10 to Trade for Breakouts

3 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patients

Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patients

Final results from a mid-stage study of Brainstorm's NurOwn therapy show a slowing of disease progression in some ALS patients.

Stocks in Whipsaw to Start 2015 as Weak Manufacturing Blunts Optimism

Stocks in Whipsaw to Start 2015 as Weak Manufacturing Blunts Optimism

Wall Street will likely excuse the bumpy start to the year as traders focus on a busy week ahead.